NASDAQ:PTI - Proteostasis Therapeutics Stock Price, Price Target & More

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Proteostasis Therapeutics Inc (NASDAQ:PTI) released its earnings results on Wednesday, May, 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.21. The company had revenue of $0.94 million for the quarter, compared to the consensus estimate of $1.03 million. Proteostasis Therapeutics had a negative net margin of 1,052.11% and a negative return on equity of 101.44%. View Proteostasis Therapeutics' Earnings History.

4 brokers have issued 1 year price targets for Proteostasis Therapeutics' stock. Their forecasts range from $5.00 to $25.00. On average, they expect Proteostasis Therapeutics' share price to reach $13.25 in the next year. This suggests a possible upside of 385.3% from the stock's current price. View Analyst Ratings for Proteostasis Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Proteostasis Therapeutics include Albireo Pharma (ALBO), Savara (SVRA), Syros Pharmaceuticals (SYRS), Concert Pharmaceuticals (CNCE), GTX (GTXI), Kindred Biosciences (KIN), Ra Pharmaceuticals (RARX), Vital Therapies (VTL), MediciNova (MNOV), Clementia Pharmaceuticals (CMTA), Avid Bioservices (CDMO), BioSpecifics Technologies (BSTC), Paratek Pharmaceuticals (PRTK), Seres Therapeutics (MCRB) and Sienna Biopharmaceuticals (SNNA).

(PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Media coverage about PTI stock has been trending somewhat positive on Monday, according to Accern. The research group identifies negative and positive press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Proteostasis Therapeutics earned a media sentiment score of 0.24 on Accern's scale. They also gave news coverage about the company an impact score of 46.73 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PTI stock can currently be purchased for approximately $2.73.

Proteostasis Therapeutics has a market capitalization of $98.50 million and generates $5.34 million in revenue each year. The company earns $-59,430,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Proteostasis Therapeutics employs 52 workers across the globe.

Proteostasis Therapeutics' mailing address is 80 GUEST STREET 5TH FLOOR, BOSTON MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]